Sam Brusco, Associate Editor08.04.22
Bio-Rad Laboratories has begun a deal to acquire Curiosity Diagnostics from Scope Fluidics, a Warsaw, Poland-based developer of tech solutions for the diagnostic and healthcare markets. The deal is valued at total consideration of up to $170 million.
Curiosity Diagnostics, a late-stage, pre-commercial platform company, is developing a sample-to-answer, rapid diagnostics PCR system.
“We are excited to have the Curiosity Diagnostics team join Bio-Rad’s Clinical Diagnostics Group and to work closely together to bring a new generation of rapid PCR systems to market,” Dara Wright, Bio-Rad’s EVP and president, Clinical Diagnostics Group, told the press. “Curiosity’s PCR platform, PCR|ONE, offers a streamlined workflow and rapid turnaround times, and is expected to extend our reach beyond high-complexity labs into near-patient molecular diagnostics labs.”
Scope Fluidics president and co-founder, Professor Piotr Garstecki, added, “Our passion at Scope Fluidics is developing innovative technologies addressing the greatest challenges in global health. The dedicated, entrepreneurial team of highly skilled, specialized personnel of Curiosity Diagnostics is looking forward to further developing the PCR|ONE technology under Bio-Rad’s leadership while we at Scope Fluidics continue to pursue new and current projects in disruptive medical diagnostics.”
Curiosity Diagnostics, a late-stage, pre-commercial platform company, is developing a sample-to-answer, rapid diagnostics PCR system.
“We are excited to have the Curiosity Diagnostics team join Bio-Rad’s Clinical Diagnostics Group and to work closely together to bring a new generation of rapid PCR systems to market,” Dara Wright, Bio-Rad’s EVP and president, Clinical Diagnostics Group, told the press. “Curiosity’s PCR platform, PCR|ONE, offers a streamlined workflow and rapid turnaround times, and is expected to extend our reach beyond high-complexity labs into near-patient molecular diagnostics labs.”
Scope Fluidics president and co-founder, Professor Piotr Garstecki, added, “Our passion at Scope Fluidics is developing innovative technologies addressing the greatest challenges in global health. The dedicated, entrepreneurial team of highly skilled, specialized personnel of Curiosity Diagnostics is looking forward to further developing the PCR|ONE technology under Bio-Rad’s leadership while we at Scope Fluidics continue to pursue new and current projects in disruptive medical diagnostics.”